Sunshine Biopharma Inc. — Form 8-K
Filed October 9, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 82/100
What the filing says
Sunshine Biopharma (NASDAQ: SBFM, market cap ~$7.1M) closed a best-efforts public offering on October 9, 2026, raising $6.0 million gross from sale of 10,909,082 common units at $0.55 per unit. Each unit includes one common share (or pre-funded warrant exercisable at $0.00001) plus two Series D warrants (exercise price $0.66, 5-year term). Total potential proceeds including warrant exercise: ~$20.4 million. Aegis Capital Corp. is exclusive placement agent (7% commission plus 1% expense allowance). Registration statement (Form S-1, File 333-299274) became effective October 7, 2026. Closing expected October 9, 2026. Net proceeds for general corporate purposes and working capital.
Why this rating
At $7.1M market cap, a $6M immediate raise (~85% of company size) plus up to $20.4M total is transformational capital infusion—dramatic increase to cash runway and operating capacity. Warrants introduce dilution risk but provide upside optionality.
Price action (we called it positive)
at our read pending | +10 min pending | +30 min pending | +1 hr pending | +4 hrs pending |
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from October 9, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.